Christian Diego Rolfo
The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute · 627 works · 22,776 citations · h-index 63
Top works
- Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
- Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer
- Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC
- Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer
- Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study
- Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trials
- KRAS oncogene in non-small cell lung cancer: clinical perspectives on the treatment of an old target
- Primary tumor sidedness has an impact on prognosis and treatment outcome in metastatic colorectal cancer: results from two randomized first-line panitumumab studies
- PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis
- RET fusions in solid tumors
- Entrectinib: a potent new TRK, ROS1, and ALK inhibitor
- Targeting c-MET in gastrointestinal tumours: rationale, opportunities and challenges
- Molecular basis and rationale for combining immune checkpoint inhibitors with chemotherapy in non-small cell lung cancer
- 385P Patient reported outcomes (PROs) analysis for patients with ROS1 fusion-positive (ROS1+) non-small cell lung cancer (NSCLC) receiving entrectinib in the global phase II STARTRK-2 study
- Profile of the Roche cobas® EGFR mutation test v2 for non-small cell lung cancer
- A Comparison of Cell-Free DNA Isolation Kits
- The role of Nuclear Factor-kappa B signaling in human cervical cancer
- Early and locally advanced non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
- Circulating cell-free nucleic acids and platelets as a liquid biopsy in the provision of personalized therapy for lung cancer patients
- FGFR a promising druggable target in cancer: Molecular biology and new drugs